Longeveron’s Lomecel-B Approved by FDA for Rare Pediatric Disease Designation
Longeveron Inc. (NASDAQ: LGVN) has received approval for Rare Pediatric Disease Designation for Lomecel-B by the FDA to treat Hypoplastic Left Heart Syndrom. HLHS is a rare life-threatening congenital heart defect in infants. Lomecel-B is an investigational allogeneic bone marrow derived medicinal signaling cell product that is being evaluated in a Phase 2 trial. “We …
Longeveron’s Lomecel-B Approved by FDA for Rare Pediatric Disease Designation Read More »